A Japan Patent on ITE for Cancer Intervention and Possible Eradication Issued to AhR Pharmaceuticals, Inc.

    MADISON, WI, November 08, 2014 /24-7PressRelease/ -- A Japan patent has been issued to AhR Pharmaceuticals, Inc. by the Japan Patent Office (JPO). The issued Japan patent covers the use of ITE and its structural analogs for cancer intervention and possible eradication in Japan.

ITE is an endogenous ligand or natural hormone for the aryl hydrocarbon receptor. Once binding to the receptor, ITE activates and drives the hormone-receptor complex in mediating a series of important biological and pharmacological processes in the body. Evidences collected by scientists from AhR Pharmaceuticals and a global research community as well have demonstrated ITE's potentials in treating cancer, obesity, and disorders related to imbalanced actions of immune systems.

"We are committed to the building of a strong intellectual property system in developing a unique treatment and possible cure for cancer patients and this is another testimony of our effective efforts in innovation and invention in the area," said Dr. Jiasheng (Jason) Song, the Chief Scientific Officer of AhR Pharmaceuticals. "We will continue the efforts in protecting our important inventions and building values for our investors," continued Dr. Song. "More importantly, by doing that, it will ultimately enable us to do tremendously good things to benefit our patients around the globe."

The patent (JP 5598775 B2) is entitled "ITE for Cancer Intervention and Eradication". The inventor of the patent is Dr. Jiasheng (Jason) Song, the major inventor of ITE technologies and Chief Scientific Officer of AhR Pharmaceuticals (the assignee and owner of the issued Japan patent). To obtain the full text of the issued Japan patent, please follow the link: http://www.ahrpharma.com/Files/AhR_Patents/AhR-Issued-JP-5598775-ITE-Cancer-Interven-Eradicat.pdf

AhR Pharmaceuticals, Inc., with licensed ITE technologies as its foundational intellectual property from Wisconsin Alumni Research Foundation (WARF, the intellectual property manager of University of Wisconsin-Madison, a world-renowned research university), is devoted to the development of the natural hormone ITE into an efficacious and sustainable but low side-effect therapeutic agent in intervention and possible eradication of cancer, obesity, and disorders due to imbalanced actions of immune systems. For more information on AhR Pharmaceuticals, Inc., its technologies, and research activities, please visit http://www.ahrpharma.com.

# # #